Literature DB >> 31235557

In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model.

Marguerite L Monogue1,2, Jennifer Tabor-Rennie1, Kamilia Abdelraouf1, David P Nicolau3,4.   

Abstract

We describe the in vivo efficacy of human-simulated WCK 5222 (cefepime-zidebactam) exposure against multidrug-resistant Pseudomonas aeruginosa (meropenem MICs 8 to >256 μg/ml) in a neutropenic murine thigh infection model. WCK 5222 MICs ranged from 4 to 32 μg/ml. Substantial in vivo WCK 5222 activity was observed against all isolates, further enhancing the efficacy of zidebactam alone in 11/16 isolates (WCK 5222 mean reduction, -1.62 ± 0.58 log10 CFU/thigh), and a lack of activity was observed with cefepime monotherapy.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  human simulated; pharmacodynamics; pharmacokinetics

Mesh：

Substances：

Year:  2019        PMID： 31235557      PMCID： PMC6591597          DOI： 10.1128/AAC.00233-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234.

Authors:  Krisztina M Papp-Wallace; Nhu Q Nguyen; Michael R Jacobs; Christopher R Bethel; Melissa D Barnes; Vijay Kumar; Saralee Bajaksouzian; Susan D Rudin; Philip N Rather; Satish Bhavsar; Tadiparthi Ravikumar; Prasad K Deshpande; Vijay Patil; Ravindra Yeole; Sachin S Bhagwat; Mahesh V Patel; Focco van den Akker; Robert A Bonomo
Journal:  J Med Chem       Date:  2018-04-20       Impact factor: 7.446

2.  Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers.

Authors:  Jared L Crandon; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

3.  WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones.

Authors:  Bartolome Moya; Isabel M Barcelo; Sachin Bhagwat; Mahesh Patel; German Bou; Krisztina M Papp-Wallace; Robert A Bonomo; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

4.  WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015.

Authors:  Helio S Sader; Mariana Castanheira; Michael Huband; Ronald N Jones; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

5.  WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.

Authors:  Helio S Sader; Paul R Rhomberg; Robert K Flamm; Ronald N Jones; Mariana Castanheira
Journal:  J Antimicrob Chemother       Date:  2017-06-01       Impact factor: 5.790

6.  Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult Subjects.

Authors:  Keith A Rodvold; Mark H Gotfried; Rakesh Chugh; Mugdha Gupta; Anasuya Patel; Rajesh Chavan; Ravindra Yeole; H David Friedland; Ashima Bhatia
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

Review 7.  Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes.

Authors:  Elizabeth B Hirsch; Vincent H Tam
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2010-08       Impact factor: 2.217

8.  Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014.

Authors:  Lindsey M Weiner; Amy K Webb; Brandi Limbago; Margaret A Dudeck; Jean Patel; Alexander J Kallen; Jonathan R Edwards; Dawn M Sievert
Journal:  Infect Control Hosp Epidemiol       Date:  2016-08-30       Impact factor: 3.254

9.  In Vivo Efficacy of Humanized WCK 5222 (Cefepime-Zidebactam) Exposures against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Thigh Model.

Authors:  Safa S Almarzoky Abuhussain; Lindsay M Avery; Kamilia Abdelraouf; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

10.  Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model.

Authors:  Lindsay M Avery; Kamilia Abdelraouf; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191
  10 in total
  12 in total

Review 1.  Is it time to move away from polymyxins?: evidence and alternatives.

Authors:  Rajeev Soman; Yamuna Devi Bakthavatchalam; Abinaya Nadarajan; Hariharan Triplicane Dwarakanathan; Ramasubramanian Venkatasubramanian; Balaji Veeraraghavan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-10-02       Impact factor: 3.267

2.  Comparative Evaluation of the In Vitro Activities of WCK 5222 (Cefepime-Zidebactam) and Combination Antibiotic Therapies against Carbapenem-Resistant Pseudomonas aeruginosa.

Authors:  Elias M Mullane; Lindsay M Avery; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

3.  WCK 5222 (Cefepime/Zidebactam) Pharmacodynamic Target Analysis against Metallo-β-lactamase producing Enterobacteriaceae in the Neutropenic Mouse Pneumonia Model.

Authors:  Alexander J Lepak; Miao Zhao; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2019-10-07       Impact factor: 5.191

Review 4.  The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations.

Authors:  Abdullah Tarık Aslan; Murat Akova
Journal:  Antibiotics (Basel)       Date:  2022-02-20

5.  In Vitro Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-Negative Bacilli Not Susceptible to Carbapenems.

Authors:  James A Karlowsky; Meredith A Hackel; Samuel K Bouchillon; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

Review 6.  The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections.

Authors:  Krisztina M Papp-Wallace
Journal:  Expert Opin Pharmacother       Date:  2019-09-09       Impact factor: 3.889

7.  In vivo efficacy of WCK 6777 (ertapenem/zidebactam) against carbapenemase-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model.

Authors:  Matthew Gethers; Iris Chen; Kamilia Abdelraouf; David P Nicolau
Journal:  J Antimicrob Chemother       Date:  2022-06-29       Impact factor: 5.758

Review 8.  Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology.

Authors:  Maxwell J Lasko; David P Nicolau
Journal:  Curr Infect Dis Rep       Date:  2020-02-07       Impact factor: 3.725

Review 9.  Antibiotics in the clinical pipeline in October 2019.

Authors:  Mark S Butler; David L Paterson
Journal:  J Antibiot (Tokyo)       Date:  2020-03-10       Impact factor: 2.649

Review 10.  New strategies and structural considerations in development of therapeutics for carbapenem-resistant Enterobacteriaceae.

Authors:  Thea Brennan-Krohn; Roman Manetsch; George A O'Doherty; James E Kirby
Journal:  Transl Res       Date:  2020-03-02       Impact factor: 7.012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.